andrewelamb
commented
2 years ago I'm not seeing those milestones for the study "Deconstruction and Reconstitution of NF1 Cutaneous Neurofibromas":
52 <chr [1]> 2020-10-31 1 12 NTAP syn11374357 geneExpression Deconstruction and Reconstitution of NF1 Cutaneous Neurofibromas
53 <chr [1]> 2020-10-31 1 1 NTAP syn11374357 protocol Deconstruction and Reconstitution of NF1 Cutaneous Neurofibromas
54 <chr [1]> 2020-10-31 1 NA NTAP syn11374357 image Deconstruction and Reconstitution of NF1 Cutaneous Neurofibromas
55 <chr [1]> 2020-10-31 1 NA NTAP syn11374357 image Deconstruction and Reconstitution of NF1 Cutaneous Neurofibromas
56 <chr [1]> 2021-04-30 2 12 NTAP syn11374357 geneExpression Deconstruction and Reconstitution of NF1 Cutaneous Neurofibromas
57 <chr [1]> 2021-04-30 2 16 NTAP syn11374357 image Deconstruction and Reconstitution of NF1 Cutaneous Neurofibromas
58 <chr [1]> 2021-04-30 2 NA NTAP syn11374357 image Deconstruction and Reconstitution of NF1 Cutaneous Neurofibromas
59 <chr [1]> 2021-04-30 2 16 NTAP syn11374357 image Deconstruction and Reconstitution of NF1 Cutaneous Neurofibromas # A tibble: 327 × 8
fileFormat date_uploadestimate reportMilestone estimatedMinNumSamples fundingAgency projectSynID dataType studyName
<list> <date> <int> <int> <chr> <chr> <chr> <chr>
1 <chr [1]> NA NA NA CTF syn22268689 immunoassay Identification and functional characterization of the substrates of LZTR1 (schwannomatosis)
2 <chr [1]> NA NA NA CTF syn22268689 image Identification and functional characterization of the substrates of LZTR1 (schwannomatosis)
3 <chr [1]> NA NA NA CTF syn22268689 cell viability Identification and functional characterization of the substrates of LZTR1 (schwannomatosis)
4 <chr [1]> NA NA NA CTF syn22268689 proteomics Identification and functional characterization of the substrates of LZTR1 (schwannomatosis)
5 <chr [1]> 2020-12-20 NA 54 CTF syn22268639 immunoflourescence Understanding the role of purinerigic signaling on tumor formation in a mouse model of Neurofibromatosis Type 1
6 <chr [1]> 2020-12-20 NA 12 CTF syn22268639 immunoassay Understanding the role of purinerigic signaling on tumor formation in a mouse model of Neurofibromatosis Type 1
7 <chr [1]> 2021-06-20 NA 12 CTF syn22268639 immunoassay Understanding the role of purinerigic signaling on tumor formation in a mouse model of Neurofibromatosis Type 1
8 <chr [1]> 2021-06-20 NA 15 CTF syn22268639 immunoflourescence Understanding the role of purinerigic signaling on tumor formation in a mouse model of Neurofibromatosis Type 1
9 <chr [1]> 2020-12-31 NA 50 CTF syn22267284 proteomics Mapping and Identifying the Roles of Protein Glycosylation in Neurofibromatosis 1
10 <chr [1]> 2021-06-30 NA 100 CTF syn22267284 immunoassay Mapping and Identifying the Roles of Protein Glycosylation in Neurofibromatosis 1
11 <chr [1]> 2021-01-01 NA 100 CTF syn22267284 mass spectrometry Mapping and Identifying the Roles of Protein Glycosylation in Neurofibromatosis 1
12 <chr [1]> 2021-01-01 NA 100 CTF syn22267284 image Mapping and Identifying the Roles of Protein Glycosylation in Neurofibromatosis 1
13 <chr [1]> 2021-06-30 NA 10 CTF syn22267284 geneExpression Mapping and Identifying the Roles of Protein Glycosylation in Neurofibromatosis 1
14 <chr [1]> 2020-12-31 NA 100 CTF syn22267284 enzyme kinetics Mapping and Identifying the Roles of Protein Glycosylation in Neurofibromatosis 1
15 <chr [1]> 2021-05-01 NA 50 CTF syn22267330 kinetic calcium flux Malignant Peripheral Nerve Sheath Tumors Achilles Heel: Combinatorial Targeting of ERBB3 and Calcium Signaling
16 <chr [1]> 2020-12-01 NA 25 CTF syn22267330 immunoassay Malignant Peripheral Nerve Sheath Tumors Achilles Heel: Combinatorial Targeting of ERBB3 and Calcium Signaling
17 <chr [1]> 2021-03-01 NA 50 CTF syn22267330 cell viability Malignant Peripheral Nerve Sheath Tumors Achilles Heel: Combinatorial Targeting of ERBB3 and Calcium Signaling
18 <chr [1]> 2021-12-01 NA 50 CTF syn22267330 cell viability Malignant Peripheral Nerve Sheath Tumors Achilles Heel: Combinatorial Targeting of ERBB3 and Calcium Signaling
19 <chr [1]> 2020-12-01 NA 35 CTF syn22267330 image Malignant Peripheral Nerve Sheath Tumors Achilles Heel: Combinatorial Targeting of ERBB3 and Calcium Signaling
20 <chr [1]> 2021-03-01 NA 50 CTF syn22267330 image Malignant Peripheral Nerve Sheath Tumors Achilles Heel: Combinatorial Targeting of ERBB3 and Calcium Signaling
21 <chr [1]> 2020-12-01 NA 80 CTF syn22268652 immunoassay The use of novel YAP/TEAD Hippo pathway inhibitors to target Merlin (NF2) null tumors
22 <chr [1]> 2021-07-01 NA 80 CTF syn22268652 immunoassay The use of novel YAP/TEAD Hippo pathway inhibitors to target Merlin (NF2) null tumors
23 <chr [1]> 2021-02-01 NA 160 CTF syn22268652 proliferation The use of novel YAP/TEAD Hippo pathway inhibitors to target Merlin (NF2) null tumors
24 <chr [1]> 2022-03-01 NA 40 CTF syn22268652 weight The use of novel YAP/TEAD Hippo pathway inhibitors to target Merlin (NF2) null tumors
25 <chr [1]> 2020-12-01 NA 144 CTF syn22266606 proteomics Unveiling the molecular mechanisms of neurofibromin regulation for therapeutic targeting in neurofibromatosis type 1
26 <chr [1]> 2022-06-30 NA 2000 CTF syn22266606 immunoassay Unveiling the molecular mechanisms of neurofibromin regulation for therapeutic targeting in neurofibromatosis type 1
27 <chr [1]> 2022-06-30 NA 100 CTF syn22266606 weight Unveiling the molecular mechanisms of neurofibromin regulation for therapeutic targeting in neurofibromatosis type 1
28 <chr [1]> NA NA 24 CTF syn22267323 metabolomics Impact of PRC2 loss on Glutamine metabolism in MPNSTs
29 <chr [2]> 2020-07-31 1 1 NTAP syn11374345 genomicVariant Leveraging human induced pluripotent stem cells (iPSCs) to determine the impact of patient-derived NF1 gene mutations on peripheral …
30 <chr [1]> 2020-07-31 1 5 NTAP syn11374345 immunoassay Leveraging human induced pluripotent stem cells (iPSCs) to determine the impact of patient-derived NF1 gene mutations on peripheral …
31 <chr [1]> 2021-01-31 2 NA NTAP syn11374345 immunoassay Leveraging human induced pluripotent stem cells (iPSCs) to determine the impact of patient-derived NF1 gene mutations on peripheral …
32 <chr [1]> 2021-01-31 2 3 NTAP syn11374345 report Leveraging human induced pluripotent stem cells (iPSCs) to determine the impact of patient-derived NF1 gene mutations on peripheral …
33 <chr [2]> 2020-02-29 1 NA NTAP syn11374341 geneExpression Microenvironmental targets of cutaneous neurofibromas: T-cells and mast cells as tumor contributors
34 <chr [2]> 2020-02-29 1 20 NTAP syn11374341 image Microenvironmental targets of cutaneous neurofibromas: T-cells and mast cells as tumor contributors
35 <chr [1]> 2020-02-29 1 1 NTAP syn11374341 protocol Microenvironmental targets of cutaneous neurofibromas: T-cells and mast cells as tumor contributors
36 <chr [1]> 2020-08-31 2 20 NTAP syn11374341 proteomics Microenvironmental targets of cutaneous neurofibromas: T-cells and mast cells as tumor contributors
37 <chr [1]> 2021-02-28 3 20 NTAP syn11374341 proteomics Microenvironmental targets of cutaneous neurofibromas: T-cells and mast cells as tumor contributors
38 <chr [1]> 2020-02-29 1 NA NTAP syn4939918 geneExpression Perpetuating NF1 heterozygous and NF1 homozygous negative plexiform neurofibroma-derived tumor cells through the generation of induc…
39 <chr [3]> 2020-02-29 1 NA NTAP syn4939918 gene expression, genomic variants Perpetuating NF1 heterozygous and NF1 homozygous negative plexiform neurofibroma-derived tumor cells through the generation of induc…
40 <chr [1]> 2020-02-29 1 NA NTAP syn4939918 NA Perpetuating NF1 heterozygous and NF1 homozygous negative plexiform neurofibroma-derived tumor cells through the generation of induc…
41 <chr [1]> 2020-02-29 1 NA NTAP syn4939918 image Perpetuating NF1 heterozygous and NF1 homozygous negative plexiform neurofibroma-derived tumor cells through the generation of induc…
42 <chr [1]> 2021-02-28 2 NA NTAP syn4939918 image Perpetuating NF1 heterozygous and NF1 homozygous negative plexiform neurofibroma-derived tumor cells through the generation of induc…
43 <chr [1]> 2021-02-28 2 NA NTAP syn4939918 NA Perpetuating NF1 heterozygous and NF1 homozygous negative plexiform neurofibroma-derived tumor cells through the generation of induc…
44 <chr [1]> 2021-02-28 2 NA NTAP syn4939918 NA Perpetuating NF1 heterozygous and NF1 homozygous negative plexiform neurofibroma-derived tumor cells through the generation of induc…
45 <chr [1]> 2021-02-28 2 NA NTAP syn4939918 ImmunoAssay Perpetuating NF1 heterozygous and NF1 homozygous negative plexiform neurofibroma-derived tumor cells through the generation of induc…
46 <chr [1]> NA NA NA NTAP syn4939918 NA Perpetuating NF1 heterozygous and NF1 homozygous negative plexiform neurofibroma-derived tumor cells through the generation of induc…
47 <chr [1]> 2020-01-31 1 NA NTAP syn11374333 image Cutaneous Neurofibroma - Models, Biology, and Translation
48 <chr [1]> 2020-01-31 1 NA NTAP syn11374333 image Cutaneous Neurofibroma - Models, Biology, and Translation
49 <chr [1]> 2021-01-31 2 NA NTAP syn11374333 image Cutaneous Neurofibroma - Models, Biology, and Translation
50 <chr [1]> 2021-01-31 2 NA NTAP syn11374333 Drug sensitivity Cutaneous Neurofibroma - Models, Biology, and Translation
51 <chr [1]> 2021-01-31 2 NA NTAP syn11374333 Results Cutaneous Neurofibroma - Models, Biology, and Translation
52 <chr [1]> 2020-10-31 1 12 NTAP syn11374357 geneExpression Deconstruction and Reconstitution of NF1 Cutaneous Neurofibromas
53 <chr [1]> 2020-10-31 1 1 NTAP syn11374357 protocol Deconstruction and Reconstitution of NF1 Cutaneous Neurofibromas
54 <chr [1]> 2020-10-31 1 NA NTAP syn11374357 image Deconstruction and Reconstitution of NF1 Cutaneous Neurofibromas
55 <chr [1]> 2020-10-31 1 NA NTAP syn11374357 image Deconstruction and Reconstitution of NF1 Cutaneous Neurofibromas
56 <chr [1]> 2021-04-30 2 12 NTAP syn11374357 geneExpression Deconstruction and Reconstitution of NF1 Cutaneous Neurofibromas
57 <chr [1]> 2021-04-30 2 16 NTAP syn11374357 image Deconstruction and Reconstitution of NF1 Cutaneous Neurofibromas
58 <chr [1]> 2021-04-30 2 NA NTAP syn11374357 image Deconstruction and Reconstitution of NF1 Cutaneous Neurofibromas
59 <chr [1]> 2021-04-30 2 16 NTAP syn11374357 image Deconstruction and Reconstitution of NF1 Cutaneous Neurofibromas
60 <chr [1]> 2020-03-21 1 NA NTAP syn11374337 protocol Use of the mouse model of cutaneous neurofibromas for identification of cells of origin and drug screening studies
61 <chr [2]> 2020-03-21 4 2 NTAP syn11374337 geneExpression Use of the mouse model of cutaneous neurofibromas for identification of cells of origin and drug screening studies
62 <chr [1]> 2020-03-21 1 NA NTAP syn11374337 image Use of the mouse model of cutaneous neurofibromas for identification of cells of origin and drug screening studies
63 <chr [1]> 2020-12-30 2 NA NTAP syn11374337 geneExpression Use of the mouse model of cutaneous neurofibromas for identification of cells of origin and drug screening studies
64 <chr [1]> 2020-12-30 2 NA NTAP syn11374337 image Use of the mouse model of cutaneous neurofibromas for identification of cells of origin and drug screening studies
65 <chr [2]> 2020-12-30 2 2 NTAP syn11374337 geneExpression Use of the mouse model of cutaneous neurofibromas for identification of cells of origin and drug screening studies
66 <chr [1]> 2021-05-01 NA 20 CTF syn23532273 image Exploiting macropinocytosis for therapeutic delivery to Nf2-deficient schwannoma cells
67 <chr [1]> 2021-05-01 NA 60 CTF syn23532273 image Exploiting macropinocytosis for therapeutic delivery to Nf2-deficient schwannoma cells
68 <chr [1]> 2021-10-31 NA 300 CTF syn23532273 image Exploiting macropinocytosis for therapeutic delivery to Nf2-deficient schwannoma cells
69 <chr [1]> 2021-10-31 NA 300 CTF syn23532273 image Exploiting macropinocytosis for therapeutic delivery to Nf2-deficient schwannoma cells
70 <chr [2]> 2021-03-01 NA 64 CTF syn23532255 Pharmacokinetic data TRAPping neurofibromas. Inhibition of the mitochondrial chaperone TRAP1 as an anti-neoplastic strategy for NF1-associated tumors
71 <chr [2]> 2021-05-01 NA 250 CTF syn23532255 Clinical score and survival rate TRAPping neurofibromas. Inhibition of the mitochondrial chaperone TRAP1 as an anti-neoplastic strategy for NF1-associated tumors
72 <chr [2]> 2021-07-01 NA 960 CTF syn23532255 Clinical score and survival rate TRAPping neurofibromas. Inhibition of the mitochondrial chaperone TRAP1 as an anti-neoplastic strategy for NF1-associated tumors
73 <chr [2]> 2021-11-30 NA 560 CTF syn23532255 Tumor volume TRAPping neurofibromas. Inhibition of the mitochondrial chaperone TRAP1 as an anti-neoplastic strategy for NF1-associated tumors
74 <chr [2]> 2021-11-30 NA 46 CTF syn23532255 Tumor volume and number of tumor masses TRAPping neurofibromas. Inhibition of the mitochondrial chaperone TRAP1 as an anti-neoplastic strategy for NF1-associated tumors
75 <chr [2]> 2021-11-30 NA 36 CTF syn23532255 Qualitative protein expression TRAPping neurofibromas. Inhibition of the mitochondrial chaperone TRAP1 as an anti-neoplastic strategy for NF1-associated tumors
76 <chr [2]> 2021-11-30 NA 36 CTF syn23532255 Metabolites concentration in tumor samples TRAPping neurofibromas. Inhibition of the mitochondrial chaperone TRAP1 as an anti-neoplastic strategy for NF1-associated tumors
77 <chr [2]> 2021-11-30 NA 18 CTF syn23532255 Protein expression TRAPping neurofibromas. Inhibition of the mitochondrial chaperone TRAP1 as an anti-neoplastic strategy for NF1-associated tumors
78 <chr [2]> 2021-11-30 NA 18 CTF syn23532255 Enzymatic activity TRAPping neurofibromas. Inhibition of the mitochondrial chaperone TRAP1 as an anti-neoplastic strategy for NF1-associated tumors
79 <chr [1]> 2021-11-30 NA 10 CTF syn23532255 Docking of TRAP1 inhibitors TRAPping neurofibromas. Inhibition of the mitochondrial chaperone TRAP1 as an anti-neoplastic strategy for NF1-associated tumors
80 <chr [2]> 2021-11-30 NA 30 CTF syn23532255 TRAP1 activity TRAPping neurofibromas. Inhibition of the mitochondrial chaperone TRAP1 as an anti-neoplastic strategy for NF1-associated tumors
81 <chr [2]> 2021-11-30 NA 20 CTF syn23532255 Hsp90 activity TRAPping neurofibromas. Inhibition of the mitochondrial chaperone TRAP1 as an anti-neoplastic strategy for NF1-associated tumors
82 <chr [2]> 2021-11-30 NA 40 CTF syn23532255 Enzymatic activity TRAPping neurofibromas. Inhibition of the mitochondrial chaperone TRAP1 as an anti-neoplastic strategy for NF1-associated tumors
83 <chr [2]> 2021-11-30 NA 20 CTF syn23532255 Cell viability TRAPping neurofibromas. Inhibition of the mitochondrial chaperone TRAP1 as an anti-neoplastic strategy for NF1-associated tumors
84 <chr [2]> 2021-11-30 NA 20 CTF syn23532255 Cell proliferation TRAPping neurofibromas. Inhibition of the mitochondrial chaperone TRAP1 as an anti-neoplastic strategy for NF1-associated tumors
85 <chr [2]> 2021-11-30 NA 20 CTF syn23532255 In vitro tumor growth TRAPping neurofibromas. Inhibition of the mitochondrial chaperone TRAP1 as an anti-neoplastic strategy for NF1-associated tumors
86 <chr [2]> 2021-10-15 NA 1 CTF syn23532271 immunoassay Experimental Therapeutic Evaluation of PSC5-6 using a pre-clinical Mouse Model of Neurofibromatosis Type 1
87 <chr [2]> 2021-10-15 NA 20 CTF syn23532271 image Experimental Therapeutic Evaluation of PSC5-6 using a pre-clinical Mouse Model of Neurofibromatosis Type 1
88 <chr [2]> 2021-10-15 NA 24 CTF syn23532271 weight Experimental Therapeutic Evaluation of PSC5-6 using a pre-clinical Mouse Model of Neurofibromatosis Type 1
89 <chr [2]> 2021-10-15 NA 18 CTF syn23532271 pharmacokinetic study Experimental Therapeutic Evaluation of PSC5-6 using a pre-clinical Mouse Model of Neurofibromatosis Type 1
90 <chr [1]> 2023-01-01 2 1000 NTAP syn23664726 genomicVariant Evaluating genetic modifiers of cutaneous neurofibromas in adults with Neurofibromatosis Type 1
91 <chr [1]> 2021-06-30 1 2 NTAP syn23662493 geneExpression Developing ELISA/IHC-Capable NF1 Monooclonal Antibody
92 <chr [1]> 2021-06-30 1 1 NTAP syn23662493 proteomics Developing ELISA/IHC-Capable NF1 Monooclonal Antibody
93 <chr [1]> 2021-06-30 1 5 NTAP syn23662493 immunoassay Developing ELISA/IHC-Capable NF1 Monooclonal Antibody
94 <chr [1]> 2021-06-30 1 40 NTAP syn23662493 immunoassay Developing ELISA/IHC-Capable NF1 Monooclonal Antibody
95 <chr [1]> 2021-06-30 1 49 NTAP syn23662493 image Developing ELISA/IHC-Capable NF1 Monooclonal Antibody
96 <chr [1]> 2020-12-18 NA 109 other syn23651229 mutational data, copy number alterations Ultra-low-pass whole genome sequencing of plasma cfDNA from patients with plexiform neurofibroma and malignant peripheral nerve shea…
97 <chr [2]> 2021-02-01 NA 105 CDMRP syn23639889 Immunoassay TYK2 as a Biomarker and Therapeutic Target for NF1-Associated Malignant Peripheral Nerve Sheath Tumors
98 <chr [4]> 2021-03-15 NA 18 CDMRP syn23639889 cell viability TYK2 as a Biomarker and Therapeutic Target for NF1-Associated Malignant Peripheral Nerve Sheath Tumors
99 <chr [1]> 2021-01-01 NA 6 CDMRP syn23639889 geneExpression TYK2 as a Biomarker and Therapeutic Target for NF1-Associated Malignant Peripheral Nerve Sheath Tumors
100 <chr [4]> 2021-03-15 NA 6 CDMRP syn23639889 immunoassay TYK2 as a Biomarker and Therapeutic Target for NF1-Associated Malignant Peripheral Nerve Sheath Tumors
101 <chr [2]> 2021-03-15 NA 3 CDMRP syn23639889 geneExpression TYK2 as a Biomarker and Therapeutic Target for NF1-Associated Malignant Peripheral Nerve Sheath Tumors
102 <chr [2]> 2022-01-15 NA 16 CDMRP syn23639889 weight TYK2 as a Biomarker and Therapeutic Target for NF1-Associated Malignant Peripheral Nerve Sheath Tumors
103 <chr [4]> 2022-06-15 NA 16 CDMRP syn23639889 image TYK2 as a Biomarker and Therapeutic Target for NF1-Associated Malignant Peripheral Nerve Sheath Tumors
104 <chr [1]> 2020-08-15 NA 96 GFF syn21650326 image Neuroprotection and optic nerve regeneration in a mouse NF1 OPG model
105 <chr [1]> 2020-05-15 NA 35 GFF syn21650326 image Neuroprotection and optic nerve regeneration in a mouse NF1 OPG model
106 <chr [1]> 2020-05-10 NA 192 GFF syn21650326 image Neuroprotection and optic nerve regeneration in a mouse NF1 OPG model
107 <chr [1]> 2020-05-10 NA 40 GFF syn21650326 image Neuroprotection and optic nerve regeneration in a mouse NF1 OPG model
108 <chr [1]> 2020-05-10 NA 4 GFF syn21650326 geneExpression Neuroprotection and optic nerve regeneration in a mouse NF1 OPG model
109 <chr [1]> 2020-12-31 NA 4 GFF syn21650395 NA Optimizing strategies to improve visual recovery from NF1 optic glioma
110 <chr [1]> 2021-03-31 NA 4 GFF syn21650395 NA Optimizing strategies to improve visual recovery from NF1 optic glioma
111 <chr [1]> 2021-12-31 NA 4 GFF syn21650395 NA Optimizing strategies to improve visual recovery from NF1 optic glioma
112 <chr [1]> 2021-12-31 NA 4 GFF syn21650395 NA Optimizing strategies to improve visual recovery from NF1 optic glioma
113 <chr [1]> 2021-06-30 NA 4 GFF syn21650395 NA Optimizing strategies to improve visual recovery from NF1 optic glioma
114 <chr [1]> 2021-12-31 NA 4 GFF syn21650395 NA Optimizing strategies to improve visual recovery from NF1 optic glioma
115 <chr [1]> 2021-03-31 NA 4 GFF syn21650395 NA Optimizing strategies to improve visual recovery from NF1 optic glioma
116 <chr [1]> 2022-03-31 NA 4 GFF syn21650395 NA Optimizing strategies to improve visual recovery from NF1 optic glioma
117 <chr [1]> 2020-12-30 NA 3 GFF syn21650404 geneExpression New strategies of protecting RGCs and promoting optic nerve regeneration
118 <chr [1]> 2020-12-30 NA 12 GFF syn21650404 geneExpression New strategies of protecting RGCs and promoting optic nerve regeneration
119 <chr [1]> 2020-09-15 NA 100 GFF syn21650464 image Structural and functional restoration of the visual system in NF1
120 <chr [1]> 2020-09-15 NA 50 GFF syn21650464 image Structural and functional restoration of the visual system in NF1
121 <chr [1]> 2020-09-15 NA 200 GFF syn21650464 image Structural and functional restoration of the visual system in NF1
122 <chr [1]> 2020-12-15 NA 200 GFF syn21650464 image Structural and functional restoration of the visual system in NF1
123 <chr [1]> 2020-12-15 NA 4 GFF syn21650464 geneExpression Structural and functional restoration of the visual system in NF1
124 <chr [1]> NA NA NA GFF syn21650476 geneExpression Generation and neuroprotective studies of NF1 patient-derived RGCs
125 <chr [1]> NA NA NA GFF syn21650476 geneExpression Generation and neuroprotective studies of NF1 patient-derived RGCs
126 <chr [1]> NA NA NA GFF syn21650476 image Generation and neuroprotective studies of NF1 patient-derived RGCs
127 <chr [1]> NA NA NA GFF syn21650476 image Generation and neuroprotective studies of NF1 patient-derived RGCs
128 <chr [1]> 2020-10-01 NA 5 GFF syn21650484 geneExpression Stem cell derived RGCs: Improving the success of transplantation strategies
129 <chr [1]> 2021-10-01 NA 5 GFF syn21650484 geneExpression Stem cell derived RGCs: Improving the success of transplantation strategies
130 <chr [1]> 2022-01-31 NA 5 GFF syn21650484 geneExpression Stem cell derived RGCs: Improving the success of transplantation strategies
131 <chr [1]> 2020-10-01 NA 50 GFF syn21650484 image Stem cell derived RGCs: Improving the success of transplantation strategies
132 <chr [1]> 2021-10-01 NA 50 GFF syn21650484 image Stem cell derived RGCs: Improving the success of transplantation strategies
133 <chr [1]> 2022-01-31 NA 50 GFF syn21650488 geneExpression Human stem cell-derived RGCs for optic nerve regeneration
134 <chr [1]> NA NA NA GFF syn21650488 geneExpression Human stem cell-derived RGCs for optic nerve regeneration
135 <chr [1]> NA NA NA GFF syn21650488 image Human stem cell-derived RGCs for optic nerve regeneration
136 <chr [1]> NA NA NA GFF syn21650488 image Human stem cell-derived RGCs for optic nerve regeneration
137 <chr [1]> NA NA 5 GFF syn21650488 chromosomal karyotypes Human stem cell-derived RGCs for optic nerve regeneration
138 <chr [1]> NA NA NA GFF syn21650493 geneExpression Retina regeneration in zebrafish-Endogenous RGC replacement
139 <chr [1]> NA NA NA GFF syn21650493 chromatinActivity Retina regeneration in zebrafish-Endogenous RGC replacement
140 <chr [1]> NA NA NA GFF syn21650493 drugScreen Retina regeneration in zebrafish-Endogenous RGC replacement
141 <chr [1]> 2021-06-30 NA 10 GFF syn21650499 geneExpression Factors that promote ganglion cell regeneration
142 <chr [2]> NA NA 60 GFF syn21650480 image RGC differentiation and transplantation for NF1 OPG
143 <chr [2]> NA NA 60 GFF syn21650366 image Axon regeneration and vision restoration in NF1 OPG
144 <chr [1]> 2020-09-30 NA 30 GFF syn21650484 Materials biodegradation Stem cell derived RGCs: Improving the success of transplantation strategies
145 <chr [3]> NA NA 20 GFF syn21650480 geneExpression RGC differentiation and transplantation for NF1 OPG
146 <chr [2]> NA NA 60 GFF syn21650480 image RGC differentiation and transplantation for NF1 OPG
147 <chr [2]> NA NA 60 GFF syn21650366 image Axon regeneration and vision restoration in NF1 OPG
148 <chr [2]> NA NA 20 GFF syn21650366 image Axon regeneration and vision restoration in NF1 OPG
149 <chr [1]> NA NA NA NA NA NA NA
150 <chr [1]> 2020-09-30 NA 23 GFF syn21650484 Materials shear modulus, time to stability Stem cell derived RGCs: Improving the success of transplantation strategies
151 <chr [1]> 2020-09-30 NA 8 GFF syn21650484 Materials Young modulus Stem cell derived RGCs: Improving the success of transplantation strategies
152 <chr [1]> 2020-09-30 NA 3 GFF syn21650484 Materials gel point imaging Stem cell derived RGCs: Improving the success of transplantation strategies
153 <chr [1]> 2020-09-30 NA 30 GFF syn21650484 Materials gel point analysis Stem cell derived RGCs: Improving the success of transplantation strategies
154 <chr [1]> 2020-09-30 NA 2 GFF syn21650484 Materials transition temperatures Stem cell derived RGCs: Improving the success of transplantation strategies
155 <chr [1]> 2020-09-30 NA 2 GFF syn21650484 Materials molecular weights Stem cell derived RGCs: Improving the success of transplantation strategies
156 <chr [1]> 2020-09-30 NA 6 GFF syn21650484 Materials chemical structure Stem cell derived RGCs: Improving the success of transplantation strategies
157 <chr [1]> 2020-09-30 NA 50 GFF syn21650484 image Stem cell derived RGCs: Improving the success of transplantation strategies
158 <chr [1]> 2020-09-30 NA 1 GFF syn21650484 image Stem cell derived RGCs: Improving the success of transplantation strategies
159 <chr [1]> 2020-09-30 NA 30 GFF syn21650484 Intensity distribution Stem cell derived RGCs: Improving the success of transplantation strategies
160 <chr [1]> 2020-09-30 NA 8 GFF syn21650484 Cell marker expression Stem cell derived RGCs: Improving the success of transplantation strategies
161 <chr [1]> 2020-09-30 NA 8 GFF syn21650484 Cell marker expression Stem cell derived RGCs: Improving the success of transplantation strategies
162 <chr [1]> 2020-09-30 NA 30 GFF syn21650484 H&E staining of retinas Stem cell derived RGCs: Improving the success of transplantation strategies
163 <chr [1]> 2020-09-30 NA 108 GFF syn21650484 Back of the eye and retina imaging Stem cell derived RGCs: Improving the success of transplantation strategies
164 <chr [1]> 2020-09-30 NA 1 GFF syn21650484 Gel presence and in vivo degradation Stem cell derived RGCs: Improving the success of transplantation strategies
165 <chr [1]> 2020-09-30 NA 250 GFF syn21650484 In vivo cell engraftment Stem cell derived RGCs: Improving the success of transplantation strategies
166 <chr [1]> 2020-09-30 NA 1 GFF syn21650484 In vivo engraftment analysis Stem cell derived RGCs: Improving the success of transplantation strategies
167 <chr [1]> 2020-09-30 NA 12 GFF syn21650484 In vivo immune response Stem cell derived RGCs: Improving the success of transplantation strategies
168 <chr [1]> 2020-09-30 NA 12 GFF syn21650484 In vivo muller cell Stem cell derived RGCs: Improving the success of transplantation strategies
169 <chr [1]> 2021-09-30 NA 10 GFF syn21650484 IPSC marker expression Stem cell derived RGCs: Improving the success of transplantation strategies
170 <chr [1]> 2021-09-30 NA 5 GFF syn21650484 IPSC gene expression Stem cell derived RGCs: Improving the success of transplantation strategies
171 <chr [1]> 2021-09-30 NA 10 GFF syn21650484 IPSC pluripotency Stem cell derived RGCs: Improving the success of transplantation strategies
172 <chr [1]> 2021-09-30 NA 30 GFF syn21650484 RGC marker characterization Stem cell derived RGCs: Improving the success of transplantation strategies
173 <chr [1]> 2021-09-30 NA 10 GFF syn21650484 RGC marker characterization Stem cell derived RGCs: Improving the success of transplantation strategies
174 <chr [1]> 2021-09-30 NA 5 GFF syn21650484 RGC gene expression Stem cell derived RGCs: Improving the success of transplantation strategies
175 <chr [1]> 2021-09-30 NA 5 GFF syn21650484 electrophysiology Stem cell derived RGCs: Improving the success of transplantation strategies
176 <chr [1]> 2021-09-30 NA 10 GFF syn21650484 RGC sorting Stem cell derived RGCs: Improving the success of transplantation strategies
177 <chr [1]> 2021-09-30 NA 50 GFF syn21650484 In vitro viability imaging Stem cell derived RGCs: Improving the success of transplantation strategies
178 <chr [1]> 2021-09-30 NA 1 GFF syn21650484 In vitro viability analysis Stem cell derived RGCs: Improving the success of transplantation strategies
179 <chr [1]> 2021-09-30 NA 10 GFF syn21650484 pRGC production stability Stem cell derived RGCs: Improving the success of transplantation strategies
180 <chr [1]> 2021-09-30 NA 10 GFF syn21650484 pRGC production release assay Stem cell derived RGCs: Improving the success of transplantation strategies
181 <chr [1]> 2020-08-31 NA 5000 GFF syn21641813 Readthrough Exploring Nonsense Suppression as a Treatment for NF1
182 <chr [1]> 2020-08-31 NA 1000 GFF syn21641813 Protein expression Exploring Nonsense Suppression as a Treatment for NF1
183 <chr [1]> 2020-08-31 NA 1000 GFF syn21641813 Protein expression Exploring Nonsense Suppression as a Treatment for NF1
184 <chr [1]> 2020-08-31 NA 500 GFF syn21641813 Protein expression Exploring Nonsense Suppression as a Treatment for NF1
185 <chr [1]> 2020-08-31 NA 500 GFF syn21641813 mRNA abundance Exploring Nonsense Suppression as a Treatment for NF1
186 <chr [1]> 2020-08-31 NA 24 GFF syn21641872 Image Genome Editing with Engineered Vectors to Correct Neurofibromatosis Type I
187 <chr [1]> 2020-08-31 NA 23 GFF syn21641872 Sanger Sequencing Genome Editing with Engineered Vectors to Correct Neurofibromatosis Type I
188 <chr [1]> 2020-08-31 NA 6 GFF syn21641872 Image Genome Editing with Engineered Vectors to Correct Neurofibromatosis Type I
189 <chr [1]> 2020-08-31 NA 4 GFF syn21641872 genomicVariants Genome Editing with Engineered Vectors to Correct Neurofibromatosis Type I
190 <chr [1]> 2020-08-31 NA 4 GFF syn21641872 geneExpression Genome Editing with Engineered Vectors to Correct Neurofibromatosis Type I
191 <chr [1]> 2020-08-31 NA 20 GFF syn21641872 Image Genome Editing with Engineered Vectors to Correct Neurofibromatosis Type I
192 <chr [1]> 2020-08-31 NA NA GFF syn21641872 Survival data Genome Editing with Engineered Vectors to Correct Neurofibromatosis Type I
193 <chr [1]> 2020-08-31 NA NA GFF syn21641872 Sequence Genome Editing with Engineered Vectors to Correct Neurofibromatosis Type I
194 <chr [1]> 2021-08-30 NA 10 GFF syn21641872 geneExpression Genome Editing with Engineered Vectors to Correct Neurofibromatosis Type I
195 <chr [1]> 2021-08-30 NA 5 GFF syn21641872 image Genome Editing with Engineered Vectors to Correct Neurofibromatosis Type I
196 <chr [1]> 2021-08-30 NA NA GFF syn21641872 image Genome Editing with Engineered Vectors to Correct Neurofibromatosis Type I
197 <chr [1]> NA NA NA GFF syn21641876 image Ataluren-promoted therapeutic nonsense suppression for neurofibromatosis
198 <chr [1]> NA NA NA GFF syn21641876 drugScreen Ataluren-promoted therapeutic nonsense suppression for neurofibromatosis
199 <chr [1]> NA NA NA GFF syn21641876 image Ataluren-promoted therapeutic nonsense suppression for neurofibromatosis
200 <chr [1]> 2020-08-31 NA NA GFF syn21641931 Protein Expression NF1 Gene Rescue in Translational Animal Models
201 <chr [1]> 2020-08-31 NA 10 GFF syn21641931 in vivo drug response NF1 Gene Rescue in Translational Animal Models
202 <chr [1]> 2020-08-31 NA 8 GFF syn21641931 in vivo drug response NF1 Gene Rescue in Translational Animal Models
203 <chr [1]> 2020-08-31 NA 10 GFF syn21641931 in vivo drug response NF1 Gene Rescue in Translational Animal Models
204 <chr [1]> 2020-08-31 NA 10 GFF syn21641931 Nanoparticle synthesis NF1 Gene Rescue in Translational Animal Models
205 <chr [1]> 2020-08-31 NA NA GFF syn21641931 Chemical structure NF1 Gene Rescue in Translational Animal Models
206 <chr [1]> 2020-08-31 NA NA GFF syn21641931 image NF1 Gene Rescue in Translational Animal Models
207 <chr [1]> 2020-08-31 NA NA GFF syn21641931 Sequence NF1 Gene Rescue in Translational Animal Models
208 <chr [1]> 2020-08-31 NA NA GFF syn21641945 geneExpression NF1 RNA Repair Based on Therapeutic Ribozymes
209 <chr [1]> 2020-08-31 NA NA GFF syn21641945 image NF1 RNA Repair Based on Therapeutic Ribozymes
210 <chr [1]> 2020-08-31 NA NA GFF syn21641945 image NF1 RNA Repair Based on Therapeutic Ribozymes
211 <chr [1]> 2020-08-31 NA NA GFF syn21641945 NA NF1 RNA Repair Based on Therapeutic Ribozymes
212 <chr [1]> 2020-08-31 NA NA GFF syn21641945 image NF1 RNA Repair Based on Therapeutic Ribozymes
213 <chr [1]> 2020-08-31 NA 8 GFF syn21641955 Guides NGS counts Investigating Synthetic Lethality Associated with NF1 Loss
214 <chr [1]> 2020-08-31 NA NA GFF syn21641955 drugScreen Investigating Synthetic Lethality Associated with NF1 Loss
215 <chr [1]> 2020-08-31 NA NA GFF syn21641955 NA Investigating Synthetic Lethality Associated with NF1 Loss
216 <chr [1]> 2020-07-01 NA 200 GFF syn21642027 image Development of Mutation Suppression Therapy in a Swine Model of NF1
217 <chr [1]> 2020-07-01 NA 100 GFF syn21642027 image Development of Mutation Suppression Therapy in a Swine Model of NF1
218 <chr [1]> 2020-07-01 NA 45 GFF syn21642027 genomicVariants Development of Mutation Suppression Therapy in a Swine Model of NF1
219 <chr [1]> 2020-07-01 NA 25 GFF syn21642027 drugScreen Development of Mutation Suppression Therapy in a Swine Model of NF1
220 <chr [1]> 2020-07-01 NA 2 GFF syn21642027 drugScreen Development of Mutation Suppression Therapy in a Swine Model of NF1
221 <chr [1]> 2020-07-01 NA 2 GFF syn21642027 spreadsheet Development of Mutation Suppression Therapy in a Swine Model of NF1
222 <chr [1]> 2020-08-31 NA NA GFF syn21642010 image Exon skipping to treat Neurofibromatosis Type 1 (NF1) mutations
223 <chr [1]> 2020-08-31 NA NA GFF syn21642010 RNA length Exon skipping to treat Neurofibromatosis Type 1 (NF1) mutations
224 <chr [1]> 2020-08-31 NA NA GFF syn21642010 Tumor size/incidence Exon skipping to treat Neurofibromatosis Type 1 (NF1) mutations
225 <chr [1]> 2020-08-31 NA NA GFF syn21642010 GTP-Ras levels Exon skipping to treat Neurofibromatosis Type 1 (NF1) mutations
226 <chr [1]> 2020-08-31 NA NA GFF syn21642010 Sequence Exon skipping to treat Neurofibromatosis Type 1 (NF1) mutations
227 <chr [1]> 2020-08-31 NA 99 GFF syn21642010 Quantification of PCR products Exon skipping to treat Neurofibromatosis Type 1 (NF1) mutations
228 <chr [1]> 2020-08-31 NA NA GFF syn21642010 Sequence Exon skipping to treat Neurofibromatosis Type 1 (NF1) mutations
229 <chr [1]> 2020-08-31 NA NA GFF syn21641985 geneExpression AAV, Zinc Finger Protein and Antisense Oligonucleotide Strategies for Restoration of Neurofibromin Expression
230 <chr [1]> 2020-08-31 NA 20 GFF syn21641985 image AAV, Zinc Finger Protein and Antisense Oligonucleotide Strategies for Restoration of Neurofibromin Expression
231 <chr [1]> 2020-08-31 NA 99 GFF syn21641985 image AAV, Zinc Finger Protein and Antisense Oligonucleotide Strategies for Restoration of Neurofibromin Expression
232 <chr [1]> 2020-08-31 NA 10 GFF syn21641985 geneExpression AAV, Zinc Finger Protein and Antisense Oligonucleotide Strategies for Restoration of Neurofibromin Expression
233 <chr [1]> 2020-08-31 NA NA GFF syn21641985 geneExpression AAV, Zinc Finger Protein and Antisense Oligonucleotide Strategies for Restoration of Neurofibromin Expression
234 <chr [1]> 2020-08-31 NA 49 GFF syn21641985 image AAV, Zinc Finger Protein and Antisense Oligonucleotide Strategies for Restoration of Neurofibromin Expression
235 <chr [1]> 2020-08-31 NA 49 GFF syn21641985 image AAV, Zinc Finger Protein and Antisense Oligonucleotide Strategies for Restoration of Neurofibromin Expression
236 <chr [1]> 2020-08-31 NA 49 GFF syn21641985 image AAV, Zinc Finger Protein and Antisense Oligonucleotide Strategies for Restoration of Neurofibromin Expression
237 <chr [1]> 2020-08-31 NA 49 GFF syn21641985 image AAV, Zinc Finger Protein and Antisense Oligonucleotide Strategies for Restoration of Neurofibromin Expression
238 <chr [1]> 2020-08-31 NA 49 GFF syn21641985 image AAV, Zinc Finger Protein and Antisense Oligonucleotide Strategies for Restoration of Neurofibromin Expression
239 <chr [1]> 2020-08-31 NA 49 GFF syn21641985 image AAV, Zinc Finger Protein and Antisense Oligonucleotide Strategies for Restoration of Neurofibromin Expression
240 <chr [1]> 2020-08-31 NA 49 GFF syn21641985 geneExpression AAV, Zinc Finger Protein and Antisense Oligonucleotide Strategies for Restoration of Neurofibromin Expression
241 <chr [1]> 2020-08-31 NA 49 GFF syn21641985 geneExpression AAV, Zinc Finger Protein and Antisense Oligonucleotide Strategies for Restoration of Neurofibromin Expression
242 <chr [1]> 2020-08-31 NA 49 GFF syn21641985 geneExpression AAV, Zinc Finger Protein and Antisense Oligonucleotide Strategies for Restoration of Neurofibromin Expression
243 <chr [1]> 2020-08-31 NA 49 GFF syn21641986 geneExpression NA
244 <NULL> NA NA NA NA syn11374354 NA A 3D Cutaneous Neurofibroma Model for Automated High-Throughput Drug Screenings
245 <NULL> NA NA NA NA syn2343195 NA Synodos NF2
246 <NULL> NA NA NA NA syn4939902 NA A Nerve Sheath Tumor Bank from Patients with Neurofibromatosis Type 1 (NF1)
247 <NULL> NA NA NA NA syn8016635 NA A Robust Plexiform Neurofibroma Model for Preclinical Drug Screening
248 <NULL> NA NA NA NA syn4939896 NA Acceptance and Commitment Training for Chronic Pain in Adolescents and Young Adults with Neurofibromatosis Type I and Plexiform Neur…
249 <NULL> NA NA NA NA syn4939872 NA Can targeted therapy prevent neurofibroma growth in mice?
250 <NULL> NA NA NA NA syn4939878 NA Development of a Child Neurofibromatosis Type 1 Health Related Quality of Life Measure
251 <NULL> NA NA NA NA syn4939876 NA Combination Index Validation Studies (2 drug combinations)
252 <NULL> NA NA NA NA syn4939880 NA Development of a needs-based quality of life Patient Reported Outcome measure specific patients with NF1-associated pNFs
253 <NULL> NA NA NA NA syn4939888 NA Development of Patient Reported Outcomes System for Patients with NF1-Associated Plexiform Neurofibromas using Mixed Method Approach
254 <NULL> NA NA NA NA syn4939906 NA Drug Screening of pNF Cell Lines
255 <NULL> NA NA NA NA syn11374353 NA Identification of pathways triggered by Schwann cell-fibroblast interactions driving cutaneous neurofibroma growth
256 <NULL> NA NA NA NA syn11374339 NA Genetic Studies of Neurofibromatosis
257 <NULL> NA NA NA NA syn12051335 NA Identifying preclinical predictors of clinical success in NF1
258 <NULL> NA NA NA NA syn4939894 NA Imaging Biomarkers of Neurofibromatosis Type 1-Associated Optic Pathway Glioma
259 <NULL> NA NA NA NA syn8016599 NA Modeling signaling networks of NF1-deficient Schwann cells and plexiform neurofibromas using mass spectrometry-based proteomics
260 <NULL> NA NA NA NA syn4939892 NA Identification of Neurofibroma Growth and Drug Resistance Pathways
261 <NULL> NA NA NA NA syn8012530 NA Neurofibromatosis Type 1 Dermal Neurofibroma Longitudinal Natural History Study and Selumetinib Clinical Trial
262 <NULL> NA NA NA NA syn4984604 NA Cutaneous Neurofibroma Data Resource
263 <NULL> NA NA NA NA syn5610446 NA Synodos NF1 Preclinical Models (Iowa Sanford Exemplar)
264 <NULL> NA NA NA NA syn5610425 NA Synodos NF1 Preclinical Models (Minnesota CCHMC Recombinetics)
265 <NULL> NA NA NA NA syn5714288 NA DHART SPORE Project 1: Molecular, Developmental, and Genetic Evaluation of Plexiform Neurofibromas to Inform Clinical Trials
266 <NULL> NA NA NA NA syn5714289 NA DHART SPORE Project 2: Targeted Therapies for Malignant Peripheral Nerve Sheath Tumors (MPNST)
267 <NULL> NA NA NA NA syn5714290 NA DHART SPORE Project 3: A High Content Clinical Trial of the MEK Inhibitor Trametinib in Juvenile Myelomonocytic Leukemia (JMML).
268 <NULL> NA NA NA NA syn5714423 NA DHART SPORE Project 4: Subsequent Malignant Neoplasms (SMNs) Among NF1 Cancer Survivors.
269 <NULL> NA NA NA NA syn5698493 NA Synodos NF1 Low Grade Glioma
270 <NULL> NA NA NA NA syn6633069 NA Columbia University NF1 Glioma Project
271 <NULL> NA NA NA NA syn7217946 NA Development of a Novel Plexiform Neurofibroma Farming System for 96-well Plate Drug Screening
272 <NULL> NA NA NA NA syn11681835 NA Novel therapeutic development of NF1-associated malignant peripheral nerve sheath tumor (MPNST)
273 <NULL> NA NA NA NA syn4939884 NA Development of a novel treatment approach to Neurofibromatosis Type 1-related MPNST using genetically engineered Clostridium novyi-NT
274 <NULL> NA NA NA NA syn4939890 NA Exploring the Plexiform Neurofibroma Interactome
275 <NULL> NA NA NA NA syn7217928 NA Plexiform Neurofibroma Model Systems for Preclinical Drug Screening
276 <NULL> NA NA NA NA syn7239560 NA Evotec Drug Target Research
277 <NULL> NA NA NA NA syn7217935 NA A primary plexiform neurofibroma cell culture model for use in cell-based high-throughput screens
278 <NULL> NA NA NA NA syn4939874 NA pNF Cell Line Characterization Studies
279 <NULL> NA NA NA NA syn7239479 NA Development of Plexiform Neurofibroma Cellular Assay for High-Throughput Screening
280 <NULL> NA NA NA NA syn7231973 NA Differentiation of NF1 heterozygous and NF1 homozygous negative iPS cells into cells of the Neural Crest-Schwann cell lineage: setti…
281 <NULL> NA NA NA NA syn11638893 NA Development of a Preclinical NF1-MPNST Platform Suitable for Precision Oncology Drug Discovery and Evaluation
282 <NULL> NA NA NA NA syn9727752 NA Synodos Schwannomatosis
283 <NULL> NA NA NA NA syn4939914 NA The Role of MEK-inhibitors for the Prevention and Treatment of Optic Pathway Gliomas in an Nf1 Deficient Mouse Model
284 <NULL> NA NA NA NA syn4939904 NA Regulation of GCPII for the Diagnosis and Treatment of Neurofibromas
285 <NULL> NA NA NA NA syn4939916 NA Screening of Plexiform Neurofibroma 3D Models
286 <NULL> NA NA NA NA syn8016577 NA Search of the molecular mechanisms sustaining plexiform neurofibroma formation in a novel three-dimensional in vitro model
287 <NULL> NA NA NA NA syn4939908 NA Prevention trial for tumor formation in mice modeling NF1 microdeletion patients
288 <NULL> NA NA NA NA syn4939910 NA Targeting the mechanisms underlying cutaneous neurofibroma formation in NF1: a clinical translational approach
289 <NULL> NA NA NA NA syn8012599 NA Testing the Pharmacologic role of Molecular Target inhibition on Plexiform Neurofibromas in a Genetically Engineered Mouse Model tha…
290 <NULL> NA NA NA NA syn11672851 NA Drug-Target Explorer
291 <NULL> NA NA NA NA syn11817821 NA NF Cell Line Compound Screens
292 <NULL> NA NA NA NA syn4939912 NA The Development and Validation of PRO Measures to Assess Pain in Individuals with NF1 and pNF
293 <NULL> NA NA NA NA syn8016650 NA TRAPping the metabolic adaptations of plexiform neurofibroma
294 <NULL> NA NA NA NA syn11374349 NA Modeling cNF with human Schwann Cells via tunable and reversible control of NF1 protein
295 <NULL> NA NA NA NA syn17098100 NA Imaging predictors of malignant peripheral nerve sheath tumors
296 <NULL> NA NA NA NA syn17100988 NA The role of GABA in the working memory impairments in Neurofibromatosis Type 1
297 <NULL> NA NA NA NA syn5562324 NA Phenotypic screening of anti-NF2 drug candidates in merlin-deficient and normal mouse Schwann cells
298 <NULL> NA NA NA NA syn18904024 NA Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.
299 <NULL> NA NA NA NA syn21452685 NA Neurofibromatosis Therapeutic Consortium - University of California, San Franciso
300 <NULL> NA NA NA NA syn20613866 NA Neurofibromatosis Therapeutic Consortium - Brigham and Women's
301 <NULL> NA NA NA NA syn22266552 NA Hexokinase 2 displacement from mitochondria-associated membranes as a new antineoplastic approach in NF1-related tumors
302 <NULL> NA NA NA NA syn21984813 NA Predictive Modeling Utilizing a Preclinical NF1-MPNST Platform Suitable for Precision Oncology
303 <NULL> NA NA NA NA syn23532258 NA Targeting the NRG1/ErbB signaling axes for the treatment of Schwannomatosis and associated pain
304 <NULL> NA NA NA NA syn24875850 NA DNA methylation signatures in peripheral leukocytes of patients with Schwannomatosis or sporadic schwannoma
305 <NULL> NA NA NA NA syn20608511 NA Whole Body MRI of NF Patients
306 <NULL> NA NA NA NA syn25881328 NA Defining the factors that dictate the pattern of glioma formation in NF1
307 <NULL> NA NA NA NA syn25961160 NA Defining the RABL6A-YAP axis in MPNST pathogenesis and therapy
308 <NULL> NA NA NA NA syn25999248 NA Targeting the Let7-HMGA2 axis in Malignant Peripheral Nerve Sheath Tumor Prevention
309 <NULL> NA NA NA NA syn25999239 NA Towards clinical translation of imaging studies in neurofibromatosis type 1
310 <NULL> NA NA NA NA syn25999950 NA Single cell sequencing of glioma in NF1 patients
311 <NULL> NA NA NA NA syn21355225 NA Evaluation of the use of antisense oligonucleotides as a personalized therapy for Neurofibromatosis Type 2 patients
312 <NULL> NA NA NA NA syn26238842 NA Signaling pathways regulated by nitrated proteins as novel therapeutic targets for neurofibromatosis type 2
313 <NULL> NA NA NA NA syn26238964 NA Human induced pluripotent stem cell modeling of sensory neuron-regulated NF1-deficient Schwann cell growth
314 <NULL> NA NA NA NA syn26238926 NA Targeting inflammatory signaling in cutaneous neurofibromas
315 <NULL> NA NA NA NA syn26241781 NA Understanding how epigenetic dysregulation and Ras misactivation cooperate during NF1 deficient Schwann cell tumorigenesis to driven…
316 <NULL> NA NA NA NA syn26347297 NA The effects of RAS signaling pathway inhibitors on tumor cells and the tumor immune microenvironment in malignant peripheral nerve s…
317 <NULL> NA NA NA NA syn26383473 NA Exploiting cytotoxic role of nuclear Rac1 to develop targeted antitumor therapy of NF2-associated tumor
318 <NULL> NA NA NA NA syn26410510 NA Neural Underpinnings of Attention in Children with NF1
319 <NULL> NA NA NA NA syn26438193 NA Pilot Study of Factors Impacting Medication Adherence in Children, Adolescents, and Adults with Neurofibromatosis Type 1 (NF1) on Cl…
320 <NULL> NA NA NA NA syn26957643 NA High-Resolution Ultrasonography and Optical Frequency Domain Imaging for Measurement and Characterization of Cutaneous Neurofibromas…
321 <NULL> NA NA NA NA syn26966057 NA Tolerability of Device Based Therapies for Neurofibromatosis Type 1 Cutaneous Neurofibromas
322 <NULL> NA NA NA NA syn27261816 NA Evaluation of a PAK1-selective PROTAC, alone and with Hippo inhibitors, as a targeted therapy in NF2
323 <NULL> NA NA NA NA syn27261848 NA Targeting endothelial cell to macrophage communication in NF1 tumors
324 <NULL> NA NA NA NA syn27261835 NA Targeting combined MEK and HDAC inhibition as an effective therapeutic strategy for NF1 high-grade glioma
325 <NULL> NA NA NA NA syn27261829 NA Preclinical Therapeutic Evaluation of ALY101 in a murine model of neurofibromatosis type 2
326 <NULL> NA NA NA NA syn27762317 NA Phenotype and genotype impact on plexiform neurofibroma response to MEK inhibition
327 <NULL> NA NA NA NA syn27761862 NA Leveraging Synodos NF2 data to test novel single and combination drugs in NF2-deficient meningioma models 
jaybee84
allaway
Describe the bug ProgressReportNumber in the Milestone Tracker is not showing milestones 3 and above for some studies.
To Reproduce Steps to reproduce the behavior:
Expected behavior All possible milestones (gathered from "ProgressReportNumber" annotation) should be reflected in the dropdown menu as well as the left hand side table in the section Sage Internal milestone or progress report tracking
Screenshots
Desktop (please complete the following information):